Myriad Genetics Inc MYGN
News
Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
